PerpEquities

SELLAS Life Sciences Group, Inc. (SLS) income statement

NASDAQ · Healthcare · Biotechnology · 13 employees · CEO Angelos Stergiou

Price
$14.69 +2.0%
Market cap
$2.78B
Enterprise value
$2.65B Data as of 2026-11-21
Last report
Q3 '26 filed 2026-11-12
Next report
2027-03-25 EPS est. -$0.05

Income statement

Income statementTrendQ4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Research & development$5.1M$5.11M$5.19M$4.36M$4.44M$3.21M$3.87M$4.22M$4.73M$5.13M$6.27M$7.03M
General & administrative$3.08M$4.53M$2.44M$2.97M$2.48M$2.86M$3M$2.87M$3.53M$4.12M$4.36M$4.28M
Operating expenses$8.18M$9.65M$7.62M$7.33M$6.92M$6.06M$6.87M$7.08M$8.26M$9.25M$10.6M$11.3M
Operating income-$8.18M-$9.65M-$7.62M-$7.33M-$6.92M-$6.06M-$6.87M-$7.08M-$8.26M-$9.25M-$10.6M-$11.3M
Interest income$41K$79K$151K$221K$181K$250K$272K$292K$597K$845K$1.02M$1.22M
Other non-operating income (gains on investments, FX ...)-$41K-$79K-$151K-$221K-$181K-$250K-$272K-$292K-$597K-$845K-$1.02M-$1.22M
Total non-operating income$41K$79K$151K$221K$181K$250K$272K$292K$597K$845K$1.02M$1.22M
Income before tax-$8.14M-$9.57M-$7.47M-$7.11M-$6.74M-$5.81M-$6.6M-$6.79M-$7.66M-$8.41M-$9.61M-$10.1M
Net income-$8.14M-$9.57M-$7.47M-$7.11M-$6.74M-$5.81M-$6.6M-$6.79M-$7.66M-$8.41M-$9.61M-$10.1M
EPS (basic)-$0.26-$0.21-$0.13-$0.10-$0.09-$0.07-$0.07-$0.06-$0.05-$0.05-$0.05-$0.05
EPS (diluted)-$0.26-$0.21-$0.13-$0.10-$0.09-$0.07-$0.07-$0.06-$0.05-$0.05-$0.05-$0.05
Shares (basic, weighted)30.8M44.8M57.5M68.3M74M87.8M94.3M108M153M172M189M202M
Shares (diluted, weighted)30.8M44.8M57.6M68.3M74M87.8M98.6M108M153M172M189M202M
Depreciation & amortization$0$0$0$0$0$0$0$7.08M$0$0$0$0
EBITDA-$8.14M-$9.57M-$7.47M-$7.11M-$6.74M-$5.81M-$6.6M$292K-$7.66M-$8.41M-$9.61M-$10.1M

Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.

Revenue, operating income and growth

quarterly

Margins

quarterly

Costs as % of revenue

quarterly

The other statements

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

Data as of 2026-11-21